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Glycopyrrolate/formoterol fumarate
metered dose inhaler for maintenance-
naïve patients with chronic obstructive
pulmonary disease: a post-hoc analysis of
the randomized PINNACLE trials
Jinping Zheng1†, Jin-fu Xu2†, Martin Jenkins3, Pryseley Nkouibert Assam4, Lijiao Wang5 and Brian J. Lipworth6*
Abstract
Background: Glycopyrrolate (GP)/formoterol fumarate (FF; GFF) metered dose inhaler is a fixed-dose combination
dual bronchodilator for patients with chronic obstructive pulmonary disease (COPD); however, whether the efficacy
in patients without current maintenance treatment is consistent with currently maintenance-treated patients is
unclear.
Methods: Data from patients who were not maintenance-treated at screening (NMT) (n = 1943) and patients who
were maintenance-treated at screening (MT) patients (n = 3040) receiving GFF, FF, GP, or placebo were pooled from
the Phase III PINNACLE studies (NCT01854645, NCT01854658, NCT02343458) for post-hoc analysis. MT patients had
received long-acting bronchodilators and/or inhaled corticosteroids in the 30 days prior to screening, and/or prior
to randomization. NMT patients had received short-acting bronchodilators or no treatment. Outcomes included
forced expiratory volume over 1 s (FEV1), clinically important deterioration (CID), rescue medication use, and safety.
Results: GFF provided significant lung function improvements at Week 24 versus placebo, GP, and FF for NMT
patients, with pre-dose trough FEV1 treatment differences of 152 (117–188) mL, 73 (45–100) mL, and 56 (29–84) mL,
respectively (least squares mean change from baseline versus comparators [95% CI]; all P < 0.0001). GFF reduced the
risk of CID by 17–43% in NMT (P ≤ 0.0157) and 18–52% (P ≤ 0.0012) in MT patients compared with monotherapy
and placebo, and reduced rescue medication use by 1.5 puffs/day over 24 weeks for both cohorts. Safety profiles
for all cohorts were consistent with each other and the parent studies.
(Continued on next page)
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Conclusions: NMT patients achieved better lung function with GFF versus monotherapy and placebo, without
increased safety risk. Dual bronchodilator therapy may offer better outcomes than monotherapy for COPD patients
when administered as first-line treatment.
Keywords: Glycopyrrolate/formoterol fumarate, Chronic obstructive pulmonary disease, Long-acting
bronchodilator-naïve,
Background
Long-acting bronchodilators are recommended as first-
line maintenance therapy for chronic obstructive
pulmonary disease (COPD) to control symptoms and
prevent exacerbations [1]. Currently, monotherapy with
either a long-acting muscarinic antagonist (LAMA) or
long-acting beta-agonist (LABA) is preferred, the excep-
tion being for stage B patients as per the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD B
patients) who experience severe breathlessness, as well
as highly symptomatic GOLD D patients. For these
groups, LAMA/LABA or LABA/inhaled corticosteroid
(ICS) combinations are indicated [1]. In patients with
persistent dyspnea, exacerbations, or exercise limitations
despite monotherapy, step-up treatment to a LAMA/
LABA combination is advised [1].
Limited evidence is available to guide the choice of
first-line maintenance therapy in COPD [1]. Studies of
maintenance treatment-naïve patients treated with
monotherapy have found safety and efficacy outcomes to
be consistent with unsorted populations, confirming that
they are an appropriate first-line option [2–4]. However,
many patients treated with monotherapy continue to
experience COPD symptoms, exacerbations, and poor
quality of life [5, 6]. In randomized trials, LAMA/LABA
combinations consistently provide superior lung func-
tion and exercise capacity improvements, and better
symptom reduction than respective monocomponents
[7–9]. A systematic review of LABA/LAMA versus
LABA, LAMA, and LABA/ICS examined 27 studies to
find significantly improved respiratory outcomes with
dual LAMA/LABA therapy [9]. Commencing new
patients directly on LAMA/LABA combinations may
improve outcomes, irrespective of GOLD stage [10–12].
However, there is limited evidence clarifying whether
dual therapy is appropriate for the initial treatment of
COPD as few studies have been conducted in patients
with lapsed or no prior history of maintenance therapy.
Glycopyrrolate/formoterol fumarate (GFF) metered
dose inhaler (MDI) is a fixed-dose combination LAMA/
LABA bronchodilator administered in a single Aero-
sphere inhaler using innovative co-suspension delivery
technology [13, 14]. In the PINNACLE trials, GFF MDI
achieved superior respiratory outcomes compared with
monotherapy and placebo in patients with COPD across
diverse treatment backgrounds [13, 14]. GFF MDI is
currently approved for long-term COPD maintenance
therapy in the USA, Europe, Canada, Australia, Japan,
and South Korea, among others.
To assess whether GFF MDI is appropriate for initial
maintenance treatment in COPD, we conducted a post-
hoc analysis comparing GFF to LAMA and LABA
monocomponents and placebo in patients not receiving
maintenance treatment at screening (NMT) and patients
receiving maintenance treatment at screening (MT)
pooled from three randomized phase III trials.
Methods
Study design
This study was a pooled, post-hoc analysis of three ran-
domized, multicenter, international, double-blind, 24-
week Phase III clinical trials, PINNACLE-1
(NCT01854645), -2 (NCT01854658), and -4
(NCT02343458), which compared the efficacy of GFF
MDI with its monocomponents and placebo. The study
details and primary outcomes have previously been pub-
lished [13, 14]. Briefly, patients were randomized to re-
ceive twice-daily GFF MDI 14.4/9.6 μg, glycopyrrolate
(GP) MDI 14.4 μg, formoterol fumarate (FF) MDI 9.6 μg,
or placebo MDI. PINNACLE-1 included a tiotropium
arm, which has been excluded from our analysis. Pa-
tients provided signed informed consent prior to screen-
ing. The studies were conducted in accordance with the
amended Declaration of Helsinki and approved by
local institutional review boards (details previously
published) [13, 14].
Participants
Enrolled subjects were aged > 40 years, from the USA,
Australia, New Zealand, Europe, and Asia (including
China and Japan), and current or former smokers (≥10
packs/year). They also had clinical history of moderate-
to-very severe COPD, defined per the American Thor-
acic Society/European Society criteria as patients with
post-bronchodilator forced expiratory volume over 1 s
(FEV1)/forced vital capacity ratio < 0.70, and FEV1 < 80%
predicted. Subjects were retrospectively classified by
treatment history. MT patients were those who received
any maintenance therapy (ICS, LAMA, LABA, or combi-
nations) during the 30 days prior to screening or prior to
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randomization. NMT patients had received short-acting
bronchodilators or remained untreated.
Outcomes and procedures
Lung function was assessed by change from baseline in
morning pre-dose trough FEV1 at Week 24, a primary
endpoint of all three parent studies. Peak change from
baseline in FEV1 within 2 h post-dosing at Week 24 was
a secondary endpoint. Spirometry was performed in ac-
cordance with the American Thoracic Society criteria.
Other secondary endpoints included time to first clinic-
ally important deterioration (CID), health-related quality
of life as assessed by St George’s Respiratory Question-
naire (SGRQ), and symptom burden as assessed by res-
cue salbutamol use over 24 weeks. First CID was defined
as the first occurrence of either ≥100 mL decline in
trough FEV1, treatment-emergent moderate or severe
COPD exacerbation, or increase of ≥4.0 units on the
SGRQ. Safety was assessed by adverse event monitoring.
Subgroup analyses were performed for the NMT cohort
in patients who were Chinese and patients who were
symptomatic (baseline COPD Assessment Test [CAT]
score ≥ 15).
Statistical analysis
Separate efficacy analyses were conducted within the
NMT and MT groups. Patients were drawn from the
intent-to-treat (ITT) populations of the parent trials, de-
fined as subjects who were randomized and received ≥1
dose of treatment (excluding tiotropium). Safety assess-
ments utilised the safety population of the parent trials.
Change from baseline in trough FEV1 was analyzed
using a repeated measures linear model that included
baseline and reversibility to salbutamol as continuous
covariates, and study, treatment, visit, and treatment by
visit interaction as categorical covariates. Similar re-
peated measures models were used for analyzing peak
FEV1, SGRQ, and salbutamol use. Time to first CID was
analyzed using a Cox regression model adjusted for
baseline percentage-predicted FEV1, baseline CAT score,
baseline eosinophil count, study, exacerbation history in
the previous year, smoking status, and baseline ICS use.
For all analyses, pairwise treatment effect estimates were
produced with 95% confidence intervals (CIs) and P-
values. These analyses were defined post-hoc, thus no ad-
justment for multiplicity was made, and they were not
prospectively powered. P-values should be regarded as
exploratory, and interpreted in terms of nominal
significance.
Results
The pooled ITT population consisted of 4983 patients
(GFF MDI, n = 1585; FF MDI, n = 1360; GP MDI, n =
1362; placebo MDI, n = 676), all of whom were included
for efficacy analyses. Patients were classified as NMT
(n = 1943) or MT (n = 3040) (Table 1). Of the NMT pa-
tients 10.0% were Chinese and 64.7% were symptomatic.
Similar demographics and baseline characteristics were
broadly observed between the NMT and MT cohorts,
and all treatment subgroups (Table 1; individual treat-
ment groups not shown). There was a higher proportion
of current smokers and subjects with moderate-severity
COPD in the NMT cohort, compared to the MT cohort.
Not unexpectedly, MT patients had longer treatment
duration, and were more likely to be GOLD D stage
than NMT patients.
Treatment with GFF MDI provided significant lung
function improvements at Week 24 versus placebo, FF,
and GP for NMT patients, with change from baseline
Table 1 Demographics and baseline characteristics
NMT
(n = 1943)
MT
(n = 3040)
Age, mean (SD), years 61.3 (8.2) 64.6 (7.8)
Sex, n (%)
Male 1193 (61.4) 1893 (62.3)
Race, n (%)
White 1563 (80.4) 2381 (78.3)
Asian 229 (11.8) 482 (15.9)
Black or African American 139 (7.2) 163 (5.4)
Other 12 (0.6) 14 (0.4)
Smoking status
Current, n (%) 1244 (64.0) 1284 (42.2)
Former, n (%) 699 (36.0) 1756 (57.8)
Number of packs/year smoked, mean (SD) 49.5 (25.9) 49.1 (26.2)
CAT score
Total CAT score, mean (SD) 17.8 (7.7) 17.0 (7.4)
Symptomatic (CAT ≥15), n (%) 1257 (64.7) 1825 (60.0)
mMRC grade, mean (SD) 1.7 (1.0) 1.8 (0.9)
COPD severity, n (%)
Mild (GOLD 1) 13 (0.7) 17 (0.6)
Moderate (GOLD 2) 1230 (63.3) 1534 (50.5)
Severe (GOLD 3) 644 (33.1) 1327 (43.7)
Very severe (GOLD 4) 56 (2.9) 162 (5.3)
GOLD 2017 category, n (%)
A 276 (14.2) 453 (14.9)
B 1516 (78.0) 2177 (71.6)
C 19 (1.0) 54 (1.8)
D 125 (6.4) 348 (11.4)
Missing 7 (0.4) 8 (0.3)
COPD duration, mean (SD), years 6.5 (6.3) 7.6 (6.2)
CAT COPD Assessment Test, COPD Chronic obstructive pulmonary disease,
GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC Modified
Medical Research Council scale, SD Standard deviation
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treatment differences in morning pre-dose trough FEV1
of 152mL, 56 mL, and 73 mL, respectively (all P <
0.0001) (Fig. 1a). The MT cohort had similar improve-
ments with GFF versus placebo, FF, and GP (treatment
differences of 140 mL, 71 mL, and 49 mL, respectively;
all P < 0.0001) (Fig. 1b). Significant differences between
GFF and all comparators were observed as early as Week
2 and maintained over 24 weeks. Similar improvements
were observed with GFF versus placebo, FF, and GP for
peak change from baseline in FEV1 within 2 h post-dose
at Week 24 (treatment differences for NMT: 283 mL, 79
mL, and 138 mL, respectively; and MT: 291 mL, 109mL,
and 133 mL, respectively; all P < 0.0001) (Fig. 1c–d).
These findings were consistent with the overall ITT
population.
GFF MDI improved CID measures for all patients. For
NMT patients, GFF MDI reduced the risk of CID by 43,
21, and 17% versus placebo, GP, and FF, respectively
(Table 2). In the MT cohort, CID risk reduction with
GFF MDI was 52, 23, and 18%, respectively, as above.
Median time to first CID, measured in weeks, was longer
for GFF (20.1) versus placebo (12.1), GP (16.0), and FF
(16.1) for NMT patients (Fig. 2; Table 2). Increased time
to first CID with GFF MDI was similarly observed in the
MT cohort. Not unexpectedly, due to the higher propor-
tion of GOLD D patients and with increased COPD
severity, median time to CID was shorter in the MT
cohort compared to NMT patients across all treatment
groups.
GFF MDI reduced total SGRQ score from baseline by
4.397 and 4.126 points for NMT and MT patients at
Week 24, respectively (Table 2). In the overall ITT
population, more patients treated with GFF (40.8%)
achieved a minimal clinically important difference
(MCID, defined as ≥4.0 units of change from baseline) in
SGRQ at Week 24 compared with FF (38.1%), GP
(35.0%), and placebo (30.9%). Rescue salbutamol use was
reduced by 1.5 puffs/day over 24 weeks compared to
baseline in subjects treated with GFF in both NMT and
MT cohorts (Table 2), and was significantly reduced
compared to placebo (P < 0.0001).
Symptomatic NMT patients treated with GFF MDI
demonstrated improved lung function at Week 24, con-
sistent with the overall NMT population. Change from
Fig. 1 Pre-dose trough and peak post-dose FEV1 for NMT (a, c) and MT (b, d) patients. P < 0.0001 for all comparisons excluding FF versus GP. All
P-values < 0.05 should only be interpreted in terms of nominal significance as the analyses in these subgroups were exploratory and post-hoc.
Interrupted line at 100 mL indicates MCID for change in trough FEV1 (1A and 1B). COPD = chronic obstructive pulmonary disease; FEV1 = forced
expiratory volume over 1 s; FF = formoterol fumarate; GFF = glycopyrrolate/formoterol fumarate; GP = glycopyrrolate; LSM = least squares mean;
MCID =minimal clinically important difference; MT =maintenance-treated at screening; NMT = not maintenance-treated at screening;
SE = standard error
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baseline in trough FEV1 was 126 mL with GFF MDI ver-
sus placebo (P < 0.0001), 49 mL versus FF (P = 0.0059),
and 73 mL versus GP (P < 0.0001). For Chinese NMT
patients, corresponding values for changes from baseline
trough FEV1 were 175 mL (P = 0.0008), 121 mL (P =
0.0017), and 103mL (P = 0.0065), respectively (Fig. 3a).
GFF MDI also improved peak change from baseline in
FEV1 in these subgroups; symptomatic NMT: 267 mL
(P < 0.0001) versus placebo, 79 mL (P < 0.0001) versus
FF, and 139 mL (P < 0.0001) versus GP; Chinese NMT:
275 mL (P < 0.0001) versus placebo, 160 mL (P = 0.0005)
versus FF, and 162 mL (P = 0.0004) versus GP (Fig. 3b).
No new safety signals were identified from the pooled
analysis. In total, 55.5 and 57.2% of patients experienced
≥1 treatment-emergent adverse event (TEAE) in the
NMT and MT cohorts, respectively, with the majority
considered non-serious and unrelated to study treatment
(Table 3). Treatment discontinuation following TEAEs
Fig. 2 Time to first CID event for NMT (a) and MT (b) patients. Time to CID (weeks) = (date of CID – first treatment administration date + 1)/7. CID
was defined as the first occurrence of one of the following events: ≥100mL decline in trough FEV1, treatment-emergent moderate or severe
COPD exacerbation, or increase of≥ 4.0 units in SGRQ score. CID = clinically important deterioration; COPD = chronic obstructive pulmonary
disease; FEV1 = forced expiratory volume in 1 s; FF = formoterol fumarate; GFF = glycopyrrolate/formoterol fumarate; GP = glycopyrrolate; MDI =
metered dose inhaler; MT =maintenance-treated at screening; NMT = not maintenance-treated at screening; SGRQ = St George’s
Respiratory Questionnaire
Fig. 3 Trough FEV1 (a) and peak post-dose FEV1 (b) in Chinese and symptomatic NMT patients. Data labels within columns are N number. * P <
0.0001, † P ≤ 0.001, and ‡ P ≤ 0.01, compared with GFF MDI. All P-values < 0.05 should only be interpreted in terms of nominal significance as the
analyses in these subgroups were exploratory and post-hoc. CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease;
FEV1 = forced expiratory volume in 1 s; FF = formoterol fumarate; GFF = glycopyrrolate/formoterol fumarate; GP = glycopyrrolate; LSM = least
squares mean; MDI = metered dose inhaler; NMT = not maintenance-treated at screening; SE = standard error
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were limited, ranging from 4.6% (FF) to 5.5% (GFF) of
NMT subjects, and 5.7% (FF) to 7.1% (placebo) of MT
subjects. Three deaths occurred in the NMT cohort (one
each in placebo, FF, and GFF subjects), and seven
occurred in the MT cohort (one each in placebo, GP,
and FF subjects, and four in GFF subjects) over the study
period; none were considered treatment-related.
Discussion
This post-hoc analysis is the first to compare GFF MDI
with its monocomponents in patients grouped by prior
exposure to maintenance therapy. Long-acting dual
bronchodilators are primarily recommended for step-up
treatment following unsatisfactory disease control with
first-line LABA or LAMA monotherapy. However, many
patients indicated for monotherapy experience ongoing
symptoms and respiratory decline during treatment [1,
5, 6]. Analyses examining whether patients may benefit
from commencing LAMA/LABA therapy directly are
emerging, but none have included GFF [15–20]. In our
analysis, GFF MDI significantly improved respiratory
outcomes for both NMT and MT cohorts compared
with monocomponents and placebo, without increasing
safety concerns. This suggests that GFF MDI may be
used as first-line therapy, achieving similar safety and
efficacy to current use. Improved stratification is needed
to identify patients who may benefit from direct dual
therapy, to avoid over-medication in those who could be
managed sufficiently with a single LAMA or LABA.
In our analysis, GFF MDI provided greater improve-
ment to morning pre-dose trough and post-dose peak
FEV1 measures from baseline, compared with mono-
components and placebo in both NMT and MT subjects
at Week 24 and over 24 weeks. GFF exceeded the MCID
for morning pre-dose trough FEV1 in both cohorts [21].
These findings are consistent with previous primary ana-
lyses of the PINNACLE studies, and consistent for the
symptomatic and Chinese NMT subgroups.
Currently, first-line LAMA/LABA combinations are
only recommended for highly symptomatic subsets of
GOLD B and D patients [1]. Unlike trials in some other
LAMA/LABA fixed-dose combinations [17, 22], the
PINNACLE studies were not restricted to symptomatic
patients. A recent pooled analysis found that respiratory
benefits for the total population were upheld in GOLD
A PINNACLE patients, classified as those with CAT
< 10/modified Medical Research Council scale of 0–1,
≤1 moderate exacerbation in the previous year, and no
exacerbations leading to hospitalization in the previous
year, suggesting GFF MDI is suitable for patients with
milder symptoms and low exacerbation risk [23]. In our
analysis, 14% of patients in the NMT and MT cohorts
Table 3 Summary of adverse events
NMT MT
Treatment GFF
(n = 638)
FF
(n = 548)
GP
(n = 516)
Placebo
(n = 241)
GFF
(n = 947)
FF
(n = 812)
GP
(n = 846)
Placebo
(n = 435)
TEAEs, n (%)
Patients with ≥1 TEAE 362 (56.7) 304 (55.5) 280 (54.3) 133 (55.2) 560 (59.1) 457 (56.3) 469 (55.4) 252 (57.9)
Patients with serious TEAEs 43 (6.7) 33 (6.0) 35 (6.8) 18 (7.5) 90 (9.5) 73 (9.0) 72 (8.5) 32 (7.4)
Deaths (all-cause) during treatment period 1 (0.2) 1 (0.2) 0 (0) 1 (0.4) 4 (0.4) 1 (0.1) 1 (0.1) 1 (0.2)
TRAEs, n (%)
Patients with TEAEs related to study treatment 75 (11.8) 58 (10.6) 51 (9.9) 19 (7.9) 97 (10.2) 86 (10.6) 99 (11.7) 50 (11.5)
Patients with serious TEAEs related to study treatment 7 (1.1) 1 (0.2) 6 (1.2) 1 (0.4) 3 (0.3) 7 (0.9) 9 (1.1) 2 (0.5)
Common TEAEs, n (%)
Upper respiratory tract infection 28 (4.4) 20 (3.6) 26 (5.0) 13 (5.4) 42 (4.4) 39 (4.8) 41 (4.8) 29 (6.7)
Viral upper respiratory tract infection 31 (4.9) 28 (5.1) 20 (3.9) 10 (4.1) 44 (4.6) 43 (5.3) 41 (4.8) 16 (3.7)
Dyspnea 11 (1.7) 8 (1.5) 7 (1.4) 7 (2.9) 24 (2.5) 27 (3.3) 25 (3.0) 19 (4.4)
Nasopharyngitis 14 (2.2) 14 (2.6) 9 (1.7) 10 (4.1) 31 (3.3) 15 (1.8) 16 (1.9) 9 (2.1)
Back pain 17 (2.7) 12 (2.2) 10 (1.9) 9 (3.7) 19 (2.0) 13 (1.6) 19 (2.2) 2 (0.5)
Cough 23 (3.6) 11 (2.0) 14 (2.7) 6 (2.5) 31 (3.3) 21 (2.6) 23 (2.7) 8 (1.8)
COPD 14 (2.2) 11 (2.0) 16 (3.1) 5 (2.1) 26 (2.7) 19 (2.3) 26 (3.1) 15 (3.4)
Bronchitis 9 (1.4) 5 (0.9) 9 (1.7) 2 (0.8) 15 (1.6) 13 (1.6) 26 (3.1) 15 (3.4)
Hypertension 14 (2.2) 5 (0.9) 6 (1.2) 8 (3.3) 14 (1.5) 16 (2.0) 14 (1.7) 16 (3.7)
Headache 15 (2.4) 17 (3.1) 11 (2.1) 3 (1.2) 15 (1.6) 18 (2.2) 20 (2.4) 4 (0.9)
Common TEAEs defined as those occurring in ≥ 3% of patients in any treatment arm. COPD Chronic obstructive pulmonary disease, FF Formoterol fumarate, GFF
Glycopyrrolate and formoterol fumarate, GP Glycopyrrolate, MT Maintenance-treated at screening, NMT Not maintenance-treated at screening, TEAE Treatment-
emergent adverse event, TRAE Treatment-related adverse event
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were classified as GOLD A. Hence, our findings support
the safety and efficacy of first-line GFF MDI for patients
with varying symptom burden.
CID is a composite measure of functional and patient-
reported outcomes, indicative of worsening COPD and
linked to poor long-term outcomes [19]. GFF reduced
the risk of CID by 17 and 21% compared with FF and
GP, respectively, and by 43% compared with placebo in
NMT subjects, suggesting the combination more effect-
ively stabilizes outcomes representative of disease pro-
gression. This trend was upheld in MT patients. SGRQ
total score, which feeds into the CID outcome as a qual-
ity of life measure, was also improved by GFF MDI for
both cohorts. CID improvements in NMT patients were
not driven by exacerbation differences, as this group
included predominately GOLD B patients who are at
low exacerbation risk.
In our study, rescue salbutamol use was reduced by
1.5 puffs/day (approximately one-third of baseline puffs/
day) over 24 weeks in NMT and MT patients treated
with GFF MDI. All comparators reduced salbutamol use
compared with placebo. A recent systematic review of
46 studies found that changes in rescue medication use
are associated with important COPD measures, includ-
ing SGRQ score, dyspnea, exacerbation rate, and trough
FEV1 [24].
No further safety findings emerged from the analysis.
TEAEs and TEAE-related discontinuations were similar
across all treatment groups and populations. These find-
ings concur with other meta-analyses and systematic re-
views, which continue to find no additional or
synergistic safety signals when LAMAs and LABAs are
used in combination [25, 26].
Preliminary analyses of other LAMA/LABA combina-
tions demonstrate that first-line dual therapy may be
more efficacious than monotherapy. Maximizing bron-
chodilation is a key outcome of maintenance therapy.
Previous analyses of monotherapies in various mainten-
ance treatment-naïve populations have found similar
safety and efficacy results to unsorted populations [2–4].
To our knowledge, maintenance treatment-naïve popu-
lations have achieved greater respiratory improvements
with dual bronchodilators over monotherapy in all
studies to date. A pre-specified subgroup analysis of
maintenance treatment-naïve and maintenance-treated
patients treated with umeclidinium/vilanterol reported
significant improvements in trough FEV1, reaching
MCID in NMT patients [15]. Better respiratory improve-
ments with dual bronchodilation were found for main-
tenance treatment-naïve patients in retrospective studies
comparing umeclidinium/vilanterol to tiotropium, and
tiotropium/olodaterol to tiotropium and placebo [16,
17]. Long-acting bronchodilator-naïve patients treated
with indacaterol, glycopyrronium, or a combination also
achieved optimal respiratory outcomes via a combin-
ation approach [18]. First-line dual bronchodilation has
been shown to reduce exacerbation risk, dyspnea, risk of
CID, and rescue medication use, whilst improving
patient-reported symptom scores, health-related quality
of life, and SGRQ scores [15–20, 27]. These data lend
further support for the preferential use of combination
treatments for first-line COPD maintenance therapy.
All but one [15] study in populations with lapsed or
no prior history of maintenance treatment, including
our own, have been designed post-hoc. These findings
are hence provisional, and there remains a paucity of
prospective data. Nonetheless, coupled with the under-
standing that effective maintenance therapy should be
commenced promptly to prevent the increased rate of
pulmonary decline observed in early disease [3, 28–33],
these findings support the case for commencing COPD
patients directly on LAMA/LABA to improve symptoms
and preserve lung function.
Limitations of our study include that the PINNACLE
trials were not prospectively powered with NMT and
MT subgroups in mind. Prospective studies of first-line
dual bronchodilator therapy are required. More targeted
subgroups would also be of interest; future research
should examine outcomes in patients who only briefly
receive LABA or LAMA monotherapy prior to escal-
ation, a common clinical occurrence, compared to those
directly prescribed dual therapy. Similarly, future re-
search should assess first-line dual LAMA/LABA treat-
ment in real-world populations.
Conclusions
Our analysis found important efficacy advantages, with
no safety, tolerability, or efficacy disadvantages to com-
mencing GFF MDI in the NMT population. These data
add to the growing body of evidence supporting LABA/
LAMA combination therapies for the first-line treatment
of moderate-to-very severe COPD in appropriate patients.
Validation of these findings with prospective and real-
world studies are required.
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